Contents

About the Editor . . . . . **vii**

Preface to "Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside" . . . . . **ix**

Musaed Alkholief, Mohd Abul Kalam, Md Khalid Anwer and Aws Alshamsan
Effect of Solvents, Stabilizers and the Concentration of Stabilizers on the Physical Properties of Poly(D,L-lactide-*co*-glycolide) Nanoparticles: Encapsulation, In Vitro Release of Indomethacin and Cytotoxicity against HepG2-Cell
Reprinted from: *Pharmaceutics* **2022**, *14*, 870, doi:10.3390/pharmaceutics14040870 . . . . . **1**

Ernest L. Vallorz, David Encinas-Basurto, Rick G. Schnellmann and Heidi M. Mansour
Design, Development, Physicochemical Characterization, and In Vitro Drug Release of Formoterol PEGylated PLGA Polymeric Nanoparticles
Reprinted from: *Pharmaceutics* **2022**, *14*, 638, doi:10.3390/pharmaceutics14030638 . . . . . **31**

David Encinas-Basurto, John P. Konhilas, Robin Polt, Meredith Hay and Heidi M. Mansour
Glycosylated Ang-(1-7) MasR Agonist Peptide Poly Lactic-co-Glycolic Acid (PLGA) Nanoparticles and Microparticles in Cognitive Impairment: Design, Particle Preparation, Physicochemical Characterization, and In Vitro Release
Reprinted from: *Pharmaceutics* **2022**, *14*, 587, doi:10.3390/pharmaceutics14030587 . . . . . **53**

Jeongrae Kim, Yongwhan Choi, Suah Yang, Jaewan Lee, Jiwoong Choi and Yujeong Moon et al.
Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses
Reprinted from: *Pharmaceutics* **2022**, *14*, 474, doi:10.3390/pharmaceutics14030474 . . . . . **67**

Jimin Hwang, Sonya Mros, Allan B. Gamble, Joel D. A. Tyndall and Arlene McDowell
Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against *Helicobacter pylori*: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles
Reprinted from: *Pharmaceutics* **2022**, *14*, 348, doi:10.3390/pharmaceutics14020348 . . . . . **85**

Maria Camilla Operti, Alexander Bernhardt, Vladimir Sincari, Eliezer Jager, Silko Grimm and Andrea Engel et al.
Industrial Scale Manufacturing and Downstream Processing of PLGA-Based Nanomedicines Suitable for Fully Continuous Operation
Reprinted from: *Pharmaceutics* **2022**, *14*, 276, doi:10.3390/pharmaceutics14020276 . . . . . **103**

Victoria O. Shipunova, Vera L. Kovalenko, Polina A. Kotelnikova, Anna S. Sogomonyan, Olga N. Shilova and Elena N. Komedchikova et al.
Targeting Cancer Cell Tight Junctions Enhances PLGA-Based Photothermal Sensitizers' Performance In Vitro and In Vivo
Reprinted from: *Pharmaceutics* **2021**, *14*, 43, doi:10.3390/pharmaceutics14010043 . . . . . **121**

Michela Varani, Giuseppe Campagna, Valeria Bentivoglio, Matteo Serafinelli, Maria Luisa Martini and Filippo Galli et al.
Synthesis and Biodistribution of ^{99m}Tc-Labeled PLGA Nanoparticles by Microfluidic Technique
Reprinted from: *Pharmaceutics* **2021**, *13*, 1769, doi:10.3390/pharmaceutics13111769 . . . . . **137**

Dalia H. Abdelkader, Ahmed Kh. Abosalha, Mohamed A. Khattab, Basmah N. Aldosari and Alanood S. Almurshedi
A Novel Sustained Anti-Inflammatory Effect of Atorvastatin—Calcium PLGA Nanoparticles: In Vitro Optimization and In Vivo Evaluation
Reprinted from: *Pharmaceutics* **2021**, *13*, 1658, doi:10.3390/pharmaceutics13101658 . . . . . **151**

Felicity Y. Han, Weizhi Xu, Vinod Kumar, Cedric S. Cui, Xaria Li and Xingyu Jiang et al.
Optimisation of a Microfluidic Method for the Delivery of a Small Peptide
Reprinted from: *Pharmaceutics* **2021**, *13*, 1505, doi:10.3390/pharmaceutics13091505 . . . . . **173**

Soumyarwit Manna, Anna M. Donnell, Rafaela Q. Caixeta Faraj, Blanca I. Riemann, Christopher D. Riemann and James J. Augsburger et al.
Pharmacokinetics and Toxicity Evaluation of a PLGA and Chitosan-Based Micro-Implant for Sustained Release of Methotrexate in Rabbit Vitreous
Reprinted from: *Pharmaceutics* **2021**, *13*, 1227, doi:10.3390/pharmaceutics13081227 . . . . . **189**

Regina Scherließ and Julia Janke
Preparation of Poly-Lactic-Co-Glycolic Acid Nanoparticles in a Dry Powder Formulation for Pulmonary Antigen Delivery
Reprinted from: *Pharmaceutics* **2021**, *13*, 1196, doi:10.3390/pharmaceutics13081196 . . . . . **201**

Vasilisa Zhukova, Nadezhda Osipova, Aleksey Semyonkin, Julia Malinovskaya, Pavel Melnikov and Marat Valikhov et al.
Fluorescently Labeled PLGA Nanoparticles for Visualization In Vitro and In Vivo: The Importance of Dye Properties
Reprinted from: *Pharmaceutics* **2021**, *13*, 1145, doi:10.3390/pharmaceutics13081145 . . . . . **215**

Anthony Cunha, Alexandra Gaubert, Laurent Latxague and Benjamin Dehay
PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases
Reprinted from: *Pharmaceutics* **2021**, *13*, 1042, doi:10.3390/pharmaceutics13071042 . . . . . **243**

Kaining Zhi, Babatunde Raji, Anantha R. Nookala, Mohammad Moshahid Khan, Xuyen H. Nguyen and Swarna Sakshi et al.
PLGA Nanoparticle-Based Formulations to Cross the Blood–Brain Barrier for Drug Delivery: From R&D to cGMP
Reprinted from: *Pharmaceutics* **2021**, *13*, 500, doi:10.3390/pharmaceutics13040500 . . . . . **267**